RYTM Earnings Date: Nov 3, 2026 (Estimated) — Rhythm Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RYTM's next earnings date?
Rhythm Pharmaceuticals, Inc. (RYTM) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.71 on revenue of $85.5M.
How did RYTM do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Rhythm Pharmaceuticals, Inc. posted EPS of -$0.73 versus the -$0.84 estimate, a beat of 13.1%. Revenue was $71.3M against a $67.2M estimate. The stock's 1-day post-earnings move was +2.9%.
How much does RYTM stock move after earnings?
RYTM beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.7% (up or down) in the day after earnings.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.84 | -0.73 | +13.10% | $71.3M | ✅ Beat | +2.92% | +12.36% | +1.91% |
| 2026-05-05 | Q1 2026 | -0.86 | -0.83 | +3.49% | $60.1M | ✅ Beat | +7.86% | +2.12% | -1.02% |
| 2026-02-26 | Q4 2025 | -0.78 | -0.73 | +6.41% | $57.3M | ✅ Beat | -1.09% | -8.22% | -17.40% |
| 2025-11-04 | Q3 2025 | -0.72 | -0.82 | -13.89% | $51.3M | ❌ Miss | -7.69% | -14.16% | -8.01% |
| 2025-08-05 | Q2 2025 | -0.67 | -0.75 | -11.94% | $48.5M | ❌ Miss | -1.85% | +4.51% | +12.69% |
| 2025-02-26 | Q4 2024 | -0.73 | -0.72 | +1.37% | $41.8M | ✅ Beat | +4.49% | +4.29% | +6.41% |
| 2024-11-05 | Q3 2024 | -0.80 | -0.73 | +8.75% | $33.3M | ✅ Beat | +11.38% | +13.88% | +2.79% |
| 2024-08-06 | Q2 2024 | -0.71 | -0.55 | +22.54% | $29.1M | ✅ Beat | +0.02% | +1.02% | +6.50% |
Showing last 8 quarters.